Redmond, WA, United States of America

Eva Kras

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eva Kras - Innovator in Self-Buffering Antibody Formulations

Introduction

Eva Kras is a notable inventor based in Redmond, WA (US). She has made significant contributions to the field of pharmaceutical formulations, particularly with her innovative work on self-buffering protein formulations. Her inventions are aimed at improving the stability and usability of pharmaceutical proteins for both veterinary and human medical applications.

Latest Patents

Eva Kras holds 1 patent for her invention titled "Self-buffering antibody formulations." This invention provides self-buffering pharmaceutical protein formulations that are substantially free of other buffering agents. The formulations maintain pH stability over extended periods, which is crucial for the distribution and storage of pharmaceutical proteins. The invention also outlines methods for designing, making, and using these formulations, which can be applied to a wide variety of proteins, particularly for treating diseases in human subjects.

Career Highlights

Eva Kras is currently associated with Amgen Inc., a leading biotechnology company. Her work focuses on developing innovative solutions that enhance the effectiveness and safety of pharmaceutical products. Her contributions have the potential to revolutionize the way proteins are formulated for medical use.

Collaborations

Eva has collaborated with esteemed colleagues such as Yatin R Gokarn and Richard L Remmele, Jr. These collaborations have further enriched her research and development efforts in the field of pharmaceutical formulations.

Conclusion

Eva Kras is a pioneering inventor whose work on self-buffering antibody formulations is set to make a significant impact in the medical field. Her innovative approach addresses critical challenges in pharmaceutical protein stability and usability.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…